CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Prasugrel Loading Dose +2 moredrug
Likely dose
Prasugrel Loading Dose 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01587651
NCT01587651Phase 4Completed
CompareCT.gov

A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents

Daiichi Sankyo·interventional·Posted Apr 30, 2012·Updated Jan 9, 2019

In Brief

A Phase 4 clinical trial evaluating Prasugrel Loading Dose, Prasugrel Maintenance Dose, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 110 participants across 13 sites in 2 countries.

Detailed Summary

This is a Phase 4, multicenter, open-label (blinded Pharmacodynamic PD results), randomized, 3-arm, parallel-design study of subjects with stable Coronary Artery Disease CAD. This study will compare the PD effect of prasugrel 10 mg QD (once-daily) maintenance dose with ticagrelor 90 mg BID (twice daily) maintenance dose in subjects with stable CAD who have previously received ticagrelor loading does (LD) and maintenance dose (MD)..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited Kingdom, United States
CollaboratorsEli Lilly and Company

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2012
Enrollment StartMar 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.2 years ago

Interventions

Prasugrel Loading Dosedrug

60mg given as six 10mg film coated tablets

Prasugrel Maintenance Dosedrug

10mg maintenance dose, given as one 10mg film coated tablet

Ticagrelor Maintenance Dosedrug

one 90mg film coated tablet